The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: A radiobiological investigation
Purpose: Using radiobiological modelling to estimate normal tissue toxicity, this study investigates the effects of dose escalation for concurrent chemoradiation therapy (CRT) in lower third oesophageal tumours on the stomach. Methods and materials: 10 patients with lower third oesophageal cancer we...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
BioMed Central
2015
|
| _version_ | 1797102800201580544 |
|---|---|
| author | Carrington, R Staffurth, J Warren, S Partridge, M Hurt, C Spezi, E Gwynne, S Hawkins, M Crosby, T |
| author_facet | Carrington, R Staffurth, J Warren, S Partridge, M Hurt, C Spezi, E Gwynne, S Hawkins, M Crosby, T |
| author_sort | Carrington, R |
| collection | OXFORD |
| description | Purpose: Using radiobiological modelling to estimate normal tissue toxicity, this study investigates the effects of dose escalation for concurrent chemoradiation therapy (CRT) in lower third oesophageal tumours on the stomach. Methods and materials: 10 patients with lower third oesophageal cancer were selected from the SCOPE 1 database (ISCRT47718479) with a mean planning target volume (PTV) of 348 cm3. The original 3D conformal plans (50Gy3D) were compared to newly created RapidArc plans of 50GyRA and 60GyRA, the latter using a simultaneous integrated boost (SIB) technique using a boost volume, PTV2. Dose-volume metrics and estimates of normal tissue complication probability (NTCP) were compared. Results: There was a significant increase in NTCP of the stomach wall when moving from the 50GyRA to the 60GyRA plans (11-17 %, Wilcoxon signed rank test, p = 0.01). There was a strong correlation between the NTCP values of the stomach wall and the volume of the stomach wall/PTV 1 and stomach wall/PTV2 overlap structures (R = 0.80 and R = 0.82 respectively) for the 60GyRA plans. Conclusion: Radiobiological modelling suggests that increasing the prescribed dose to 60Gy may be associated with a significantly increased risk of toxicity to the stomach. It is recommended that stomach toxicity be closely monitored when treating patients with lower third oesophageal tumours with 60Gy. |
| first_indexed | 2024-03-07T06:10:58Z |
| format | Journal article |
| id | oxford-uuid:ef79bf23-86dd-4084-9938-4b4a659fed18 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T06:10:58Z |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | oxford-uuid:ef79bf23-86dd-4084-9938-4b4a659fed182022-03-27T11:40:29ZThe effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: A radiobiological investigationJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ef79bf23-86dd-4084-9938-4b4a659fed18Symplectic Elements at OxfordBioMed Central2015Carrington, RStaffurth, JWarren, SPartridge, MHurt, CSpezi, EGwynne, SHawkins, MCrosby, TPurpose: Using radiobiological modelling to estimate normal tissue toxicity, this study investigates the effects of dose escalation for concurrent chemoradiation therapy (CRT) in lower third oesophageal tumours on the stomach. Methods and materials: 10 patients with lower third oesophageal cancer were selected from the SCOPE 1 database (ISCRT47718479) with a mean planning target volume (PTV) of 348 cm3. The original 3D conformal plans (50Gy3D) were compared to newly created RapidArc plans of 50GyRA and 60GyRA, the latter using a simultaneous integrated boost (SIB) technique using a boost volume, PTV2. Dose-volume metrics and estimates of normal tissue complication probability (NTCP) were compared. Results: There was a significant increase in NTCP of the stomach wall when moving from the 50GyRA to the 60GyRA plans (11-17 %, Wilcoxon signed rank test, p = 0.01). There was a strong correlation between the NTCP values of the stomach wall and the volume of the stomach wall/PTV 1 and stomach wall/PTV2 overlap structures (R = 0.80 and R = 0.82 respectively) for the 60GyRA plans. Conclusion: Radiobiological modelling suggests that increasing the prescribed dose to 60Gy may be associated with a significantly increased risk of toxicity to the stomach. It is recommended that stomach toxicity be closely monitored when treating patients with lower third oesophageal tumours with 60Gy. |
| spellingShingle | Carrington, R Staffurth, J Warren, S Partridge, M Hurt, C Spezi, E Gwynne, S Hawkins, M Crosby, T The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: A radiobiological investigation |
| title | The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: A radiobiological investigation |
| title_full | The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: A radiobiological investigation |
| title_fullStr | The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: A radiobiological investigation |
| title_full_unstemmed | The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: A radiobiological investigation |
| title_short | The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: A radiobiological investigation |
| title_sort | effect of dose escalation on gastric toxicity when treating lower oesophageal tumours a radiobiological investigation |
| work_keys_str_mv | AT carringtonr theeffectofdoseescalationongastrictoxicitywhentreatingloweroesophagealtumoursaradiobiologicalinvestigation AT staffurthj theeffectofdoseescalationongastrictoxicitywhentreatingloweroesophagealtumoursaradiobiologicalinvestigation AT warrens theeffectofdoseescalationongastrictoxicitywhentreatingloweroesophagealtumoursaradiobiologicalinvestigation AT partridgem theeffectofdoseescalationongastrictoxicitywhentreatingloweroesophagealtumoursaradiobiologicalinvestigation AT hurtc theeffectofdoseescalationongastrictoxicitywhentreatingloweroesophagealtumoursaradiobiologicalinvestigation AT spezie theeffectofdoseescalationongastrictoxicitywhentreatingloweroesophagealtumoursaradiobiologicalinvestigation AT gwynnes theeffectofdoseescalationongastrictoxicitywhentreatingloweroesophagealtumoursaradiobiologicalinvestigation AT hawkinsm theeffectofdoseescalationongastrictoxicitywhentreatingloweroesophagealtumoursaradiobiologicalinvestigation AT crosbyt theeffectofdoseescalationongastrictoxicitywhentreatingloweroesophagealtumoursaradiobiologicalinvestigation AT carringtonr effectofdoseescalationongastrictoxicitywhentreatingloweroesophagealtumoursaradiobiologicalinvestigation AT staffurthj effectofdoseescalationongastrictoxicitywhentreatingloweroesophagealtumoursaradiobiologicalinvestigation AT warrens effectofdoseescalationongastrictoxicitywhentreatingloweroesophagealtumoursaradiobiologicalinvestigation AT partridgem effectofdoseescalationongastrictoxicitywhentreatingloweroesophagealtumoursaradiobiologicalinvestigation AT hurtc effectofdoseescalationongastrictoxicitywhentreatingloweroesophagealtumoursaradiobiologicalinvestigation AT spezie effectofdoseescalationongastrictoxicitywhentreatingloweroesophagealtumoursaradiobiologicalinvestigation AT gwynnes effectofdoseescalationongastrictoxicitywhentreatingloweroesophagealtumoursaradiobiologicalinvestigation AT hawkinsm effectofdoseescalationongastrictoxicitywhentreatingloweroesophagealtumoursaradiobiologicalinvestigation AT crosbyt effectofdoseescalationongastrictoxicitywhentreatingloweroesophagealtumoursaradiobiologicalinvestigation |